BOONTON, N.J.--(BUSINESS WIRE)--Mar. 9, 2009--
Unigene Laboratories, Inc. (OTCBB: UGNE, http://www.unigene.com)
will release financial results for the year ended December 31, 2008,
after the market closes on Monday, March 16, 2009. The Company will also
host a conference call the next morning, Tuesday, March 17th at 9:00 AM
EDT, to discuss its 2008 year-end financial results and to provide a
Company update.
Unigene invites all those interested in hearing management’s discussion
to join the call by dialing (877) 407-0782 for participants in the
United States and (201) 689-8567 for international participants. A
replay will be available for seven days after the call and can be
accessed by dialing (877) 660-6853 for participants in the United States
and (201) 612-7415 for international participants. When prompted, enter
account number 286 and conference ID#314958. The conference call may
also be accessed via the Web at http://www.unigene.com;
a link will be provided for listeners to join the call.
For more news and information on Unigene Laboratories please visit www.IRGnews.com/coi/UGNE
where you can find the CEO’s video, a fact sheet on the company,
investor presentations, and more.
About Unigene
Unigene Laboratories, Inc. is a biopharmaceutical company
focusing on the oral and nasal delivery of large-market peptide drugs.
Due to the size of the worldwide osteoporosis market, Unigene is
targeting its initial efforts on developing calcitonin and PTH-based
therapies. Fortical®, Unigene’s nasal calcitonin product for
the treatment of postmenopausal osteoporosis, received FDA approval and
was launched in August 2005. Unigene has licensed the U.S. rights for
Fortical® to Upsher-Smith Laboratories, worldwide rights for
its oral PTH technology to GlaxoSmithKline and worldwide rights for its
calcitonin manufacturing technology to Novartis. Unigene’s patented oral
delivery technology has successfully delivered, in preclinical and/or
clinical trials, various peptides including calcitonin, PTH and insulin.
Unigene’s patented manufacturing technology is designed to
cost-effectively produce peptides in quantities sufficient to support
their worldwide commercialization as oral or nasal therapeutics. For
more information about Unigene, call (973) 882-0860 or visit www.unigene.com.
For information about Fortical, visit www.fortical.com.
Safe Harbor statements under the Private Securities Litigation Reform
Act of 1995: This press release contains forward-looking statements as
defined in Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended. Such
forward-looking statements are based upon Unigene Laboratories, Inc.’s
management’s current expectations, estimates, beliefs, assumptions, and
projections about Unigene’s business and industry. Words such as
“anticipates,” “expects,” “intends,” “plans,” “predicts,” “believes,”
“seeks,” “estimates,” “may,” “will,” “should,” “would,” “potential,”
“continue,” and variations of these words (or negatives of these words)
or similar expressions, are intended to identify forward-looking
statements. In addition, any statements that refer to expectations,
projections, or other characterizations of future events or
circumstances, including any underlying assumptions, are forward-looking
statements. These forward-looking statements are not guarantees of
future performance and are subject to certain risks, uncertainties, and
assumptions that are difficult to predict. Therefore, our actual results
could differ materially and adversely from those expressed in any
forward-looking statements as a result of various risk factors. These
risks and uncertainties include the risks associated with the effect of
changing economic conditions, trends in the products markets, variations
in Unigene's cash flow, market acceptance risks, technical development
risks and other risk factors detailed in Unigene's Securities and
Exchange Commission filings.
Source: Unigene Laboratories, Inc.
Unigene Investors:
The Investor Relations Group
Erika
Moran/Dian Griesel, PhD, 212-825-3210
OR
Media:
Janet
Vasquez, 212-825-3210
|
